Navigation Links
Isotechnika's Lead Drug, ISA247, To Be Highlighted at the,Association for Research in Vision and Ophthalmology (ARVO) Annual,Meeting

EDMONTON, Alberta, May 4, 2007 – Isotechnika Inc. (TSX:ISA) announced today that the Company’s lead drug, ISA247, referred to as LX211 by our partner Lux Biosciences, has been selected as the subject of two presentations at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, being held May 6-10 in Fort Lauderdale, Florida.

The first, an oral presentation being given on May 5 during a satellite session of the American Uveitis Society by Dr. Quan Dong Nguyen, Johns Hopkins University, discusses the ongoing LUMINATE (Lux Uveitis Multicenter Investigation of a New Approach to TrEatment) Phase 2/3 Clinical Trial Program. The three LUMINATE trials represent the first clinical development program aimed at supporting regulatory approval of a corticosteroid-sparing immunosuppressive agent in different types of sight-threatening, non-infectious uveitis.

The second, a poster presented by Matthew A. Cunningham, National Eye Institute, discusses preclinical data demonstrating the ability of subcutaneous injections of LX211 to prevent and reverse experimental autoimmune uveoretinitis (EAU) in rats. Cunningham commented, “We observed that in this animal model, LX211 could both prevent the onset of disease as well as reverse EAU at doses as low as 10mg/kg. These preclinical results clearly support our view that LX211 may play an important future role in the treatment of uveitis.”

“These positive preclinical results, combined with encouraging safety data from human clinical trials in other indications conducted by our partner Isotechnika, provide a strong rationale for our ongoing registration-directed LUMINATE studies of LX211 in uveitis,” said Ulrich Grau, Ph.D., Lux Biosciences’ president and chief executive officer. “We hope to complete enrollment in the LUMINATE trial program by early 2008 and, if suc cessful, seek regulatory approval for LX211 in late 2008.”

Dr. Randall Yatscoff, Isotechnika’s President & CEO commented, “We are encouraged by the preclinical data seen to date and we look forward to working with Lux Biosciences to facilitate meeting their clinical development timelines. Uveitis is the third indication that ISA247 (LX211) is currently being developed for. Late-stage clinical trials are also being conducted with ISA247 for the treatment of moderate to severe psoriasis and the prevention of kidney graft rejection.”

-30-

For More Information:

Dr. Randall Yatscoff Stephanie Gillis-Paulgaard

President & CEO Director, Corporate Communications

Isotechnika Inc. Isotechnika Inc.

780-487-1600 (247) 780-909-4661

780-484-4105 (fax) 780-484-4105 (fax)

ryatscoff@isotechnika.com sgillis-paulgaard@isotechnika.com

About Isotechnika

Edmonton-based Isotechnika Inc. is an international biopharmaceutical company focused on the discovery and development of novel immunosuppressive therapeutics that are safer than currently available treatments. Isotechnika looks to become the leader in development of immunosuppressant therapies.

Isotechnika's lead drug, ISA247, has successfully completed a Phase 3 Canadian trial for the treatment of moderate to severe psoriasis. ISA247 is currently being investigated in a combined Phase 3 European/Canadian psoriasis trial and a Phase 2b North American trial for the prevention of kidney graft rejection. On e of our partners, Lux Biosciences, has received permission from the Food and Drug Administration to investigate ISA247 in three separate pivotal Phase 2/Phase 3 trials for the treatment of non-infectious uveitis and as a maintenance therapy in uveitis.

Isotechnika Inc. is a publicly traded company on the Toronto Stock Exchange under the symbol "ISA". More information on Isotechnika can be found at www.isotechnika.com.

Partnerships with Isotechnika Inc.

Isotechnika Inc. signed a collaboration agreement with Hoffman La Roche on April 9, 2002, which licensed the worldwide rights to develop and commercialize voclosporine for all transplant indications.

On September 30, 2005, Isotechnika Inc. entered into an exclusive worldwide licensing agreement with Atrium Medical Corporation for the use of voclosporine and TAFA93 specifically with drug eluting devices for the non-systemic treatment of vascular, cardiovascular, target vessel and tissue disorders.

Isotechnika Inc. and Cellgate Inc. signed an option agreement on April 25, 2006, granting Isotechnika the option to obtain an exclusive license to develop and commercialize conjugates consisting of Cellgate's patented transporter technology for the topical delivery of voclosporine in patients suffering from mild to moderate psoriasis.

On May 25, 2006, Isotechnika Inc. signed an agreement with Lux Biosciences, Inc. of Jersey City, New Jersey granting Lux Biosciences worldwide rights to develop and commercialize Isotechnika’s lead drug, voclosporine for the treatment and prophylaxis of all ophthalmic diseases.

Forward-Looking Statements

This press release may contain forward-looking statements. Forward-looking statements, including the Company's belief as to the potential of its products, the Company's expectations regarding the issuance of additional patents a nd the Company's ability to protect its intellectual property, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the ability to economically manufacture its products, the potential of its products, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize its products, the ability of the Company to defend its patents from infringement by third parties, and the risk that the Company's patents may be subsequently shown to be invalid or infringe the patents of others. Investors should consult the Company's quarterly and annual filings with the Canadian commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements.



'"/>




Related medicine technology :

1. Isotechnikas independent data monitoring committee conducts review of phase 2b kidney transplant trial
2. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
3. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
4. Gentiums Defibrotide Highlighted in Poster Presentation at World Congress of Nephrology
5. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
6. Gentiums Defibrotide Highlighted in Two Poster Presentations at American Association for Cancer Research Annual Meeting
7. Alfacells Onconase Highlighted in Latest Edition of Handbook of Therapeutic Antibodies
8. NIEHS Researchers Identify Enzyme Critical in DNA Replication
9. Stanford Researchers Find Brain Pathway of Depression in Rats
10. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
11. From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... York , April 27, 2016 ... report titled, "Skincare Devices Market - Global Industry Analysis, ... According to the report, the global skincare devices market ... is anticipated to expand at a CAGR of 10.1% ... in 2023. Browse the full Skincare Devices Market ...
(Date:4/27/2016)... Shire plc (LSE: SHP, NASDAQ: ... Financial Officer, will present at the Deutsche Bank 41st Annual ... on Wednesday, May 04, 2016, 10:00 am EDT (15:00 BST). ... the Presentations and Webcasts section of Shire,s Investor website at ... be available on this same website for approximately 90 days. ...
(Date:4/27/2016)... , April 27, 2016 ... to reach USD 2.06 billion by 2022, according ... Inc. Increasing consumer awareness towards a healthy lifestyle ... next seven years.      (Logo: ... intake coupled with rising health treatment expenditure has ...
Breaking Medicine Technology:
(Date:4/30/2016)... ... ... of us, but there are things we can do to improve the odds of staying healthy ... more that there are simple, yet important steps that can be taken to maintain good health ... for her patients include;, , exercise , healthy diet ...
(Date:4/29/2016)... ... 29, 2016 , ... In an article published April 16th on ... Botox and lip injections, which she underwent in order to feel more at home ... Arts Festival. The article explains that Ms. Mirmelli’s situation is not unique; many plastic ...
(Date:4/29/2016)... ... ... Our bodies are bombarded daily by environmental and lifestyle factors that can ... to adopt a more healthful diet, but too many people think that food has ... and the creator of the Newport Beach Cleanse and 14-Day Eating Plan, disagrees whole-heartedly. ...
(Date:4/29/2016)... ... 2016 , ... The White House announced efforts yesterday to ... about their loan terms and accounts, and more protections for borrowers. The announcement ... private loans, has reached $1.3 trillion, with 43 million Americans holding student loans ...
(Date:4/29/2016)... Southlake, Texas (PRWEB) , ... April 29, 2016 , ... ... and neck pain, is proud to announce one of their physicians has been invited ... Osteopathic Family Physicians (Texas ACOFP) Family Practice Review conference on April 30, 2016. ...
Breaking Medicine News(10 mins):